Kymera Therapeutics Intrinsic Value – KYMERA THERAPEUTICS Reports 43.4% Year-Over-Year Increase in Total Revenue for Q2 of Fiscal Year 2023

August 27, 2023

☀️Earnings Overview

KYMERA THERAPEUTICS ($NASDAQ:KYMR) announced their financial performance for the second quarter of Fiscal Year 2023 on August 3 2023. Total revenue for the quarter amounted to USD 16.5 million, a 43.4% increase from the same period in the prior year. Net income for the quarter was reported as USD -38.8 million, a decrease from the previous year’s figure of -40.3 million.

Analysis – Kymera Therapeutics Intrinsic Value

GoodWhale has conducted an in-depth analysis of KYMERA THERAPEUTICS‘ well-being and the value of its stock. According to our proprietary Valuation Line, the fair value of a KYMERA THERAPEUTICS share stands at $34.3. However, the company’s stock is currently trading at $23.9, which implies that it is undervalued by 30.3%. This presents an opportunity for investors looking for a good deal on their investments. With this in mind, we believe that KYMERA THERAPEUTICS is a great buy at its current price. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Kymera Therapeutics. More…

    Total Revenues Net Income Net Margin
    51.67 -157.59 -305.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Kymera Therapeutics. More…

    Operations Investing Financing
    -153.03 -26.72 154.91
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Kymera Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    581.95 146.52 7.86
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Kymera Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    75.9% -304.6%
    FCF Margin ROE ROA
    -327.9% -21.9% -16.9%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The company is engaged in the discovery and development of first-in-class medicines to treat patients with severe and life-threatening diseases. Kymera Therapeutics Inc’s lead product candidate is KYM-001, which is in Phase I clinical trials for the treatment of patients with relapsed or refractory B-cell malignancies. The company’s competitors include Abionyx Pharma, Shattuck Labs Inc, and Prestige BioPharma Ltd.

    – Abionyx Pharma ($LTS:0RAG)

    Abionyx Pharma is a pharmaceutical company with a market cap of 52.78M as of 2022. The company has a Return on Equity of -37.6%. Abionyx Pharma is a company that focuses on the development and commercialization of innovative therapies for the treatment of cancer and other rare diseases.

    – Shattuck Labs Inc ($NASDAQ:STTK)

    Shattuck Labs Inc is a clinical-stage biopharmaceutical company. The company’s focus is on developing immunotherapy treatments for cancer. The company’s most advanced product candidate is an antibody-drug conjugate (ADC) that targets the protein CD70, which is expressed on the surface of many types of cancer cells.

    – Prestige BioPharma Ltd ($KOSE:950210)

    Prestige BioPharma Ltd is a biopharmaceutical company that focuses on the development, manufacture, and commercialization of innovative drugs for the treatment of cancer and other life-threatening diseases. The company has a market cap of 98.44B as of 2022 and a ROE of -28.18%. Prestige BioPharma’s products are designed to target specific molecular pathways that are involved in the development and progression of cancer. The company’s lead product candidates are PBP-101, an orally-available small molecule inhibitor of the checkpoint kinase 1 (Chk1) enzyme, and PBP-102, an antibody-drug conjugate that targets the epidermal growth factor receptor 2 (HER2).


    Investors in KYMERA THERAPEUTICS were pleased to learn that for the second quarter of Fiscal Year 2023, the company reported total revenue of USD 16.5 million, a 43.4% year-over-year increase. The positive news caused the stock price to go up on August 3 2023, indicating that investors are optimistic about the company’s performance. This is a positive sign for KYMERA THERAPEUTICS, as they strive to maintain their growth trajectory.

    Recent Posts

    Leave a Comment